Copyright © 2014 Jose ́ Sereno et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Protocols of conversion fromcyclosporinA (CsA) to sirolimus (SRL) have beenwidely used in immunotherapy after transplantation to prevent CsA-induced nephropathy, but the molecular mechanisms underlying these protocols remain nuclear. This study aimed to identify the molecular pathways and putative biomarkers of CsA-to-SRL conversion in a rat model. Four animal groups
Contains fulltext : 50114.pdf (publisher's version ) (Closed access)Recent studies...
This study was designed to evaluate whether sirolimus (SRL) conversion effectively improves renal fu...
Sirolimus (SRL), a mammalian target of rapamycin inhibitor, is widely used in transplantation, but t...
Protocols of conversion from cyclosporin A (CsA) to sirolimus (SRL) have been widely used in immunot...
Protocols of conversion from cyclosporine A (CsA) to sirolimus (SRL) have been widely used in immuno...
Sirolimus (SRL) have been pointed as a feasible option for minimize the use of cyclosporine A (CsA),...
Side-effect minimization strategies to avoid serious side-effects of cyclosporine A (CsA), such as n...
Cyclosporin (CsA) has been progressively replaced by other drugs with putatively fever side effects,...
End Stage Renal Disease (ESRD) is an ever increasing problem worldwide. However the mechanisms under...
Cyclosporin A (CsA), a calcineurin inhibitor, remain the cornerstone of immunosuppressive regimens, ...
Cyclosporin A (CsA), a calcineurin inhibitor, remain the cornerstone of immunosuppressive regimens, ...
Copyright © 2012 Bertram L. Kasiske et al. This is an open access article distributed under the Crea...
Background: Ischemia-reperfusion (I/R) is present at various degrees in kidney transplants. I/R play...
Sirolimus, a macrocylic lactone, blocks T-cell activation by a mechanism of action distinct from cal...
Conversion to sirolimus for chronic renal allograft dysfunction: risk factors for graft loss and sev...
Contains fulltext : 50114.pdf (publisher's version ) (Closed access)Recent studies...
This study was designed to evaluate whether sirolimus (SRL) conversion effectively improves renal fu...
Sirolimus (SRL), a mammalian target of rapamycin inhibitor, is widely used in transplantation, but t...
Protocols of conversion from cyclosporin A (CsA) to sirolimus (SRL) have been widely used in immunot...
Protocols of conversion from cyclosporine A (CsA) to sirolimus (SRL) have been widely used in immuno...
Sirolimus (SRL) have been pointed as a feasible option for minimize the use of cyclosporine A (CsA),...
Side-effect minimization strategies to avoid serious side-effects of cyclosporine A (CsA), such as n...
Cyclosporin (CsA) has been progressively replaced by other drugs with putatively fever side effects,...
End Stage Renal Disease (ESRD) is an ever increasing problem worldwide. However the mechanisms under...
Cyclosporin A (CsA), a calcineurin inhibitor, remain the cornerstone of immunosuppressive regimens, ...
Cyclosporin A (CsA), a calcineurin inhibitor, remain the cornerstone of immunosuppressive regimens, ...
Copyright © 2012 Bertram L. Kasiske et al. This is an open access article distributed under the Crea...
Background: Ischemia-reperfusion (I/R) is present at various degrees in kidney transplants. I/R play...
Sirolimus, a macrocylic lactone, blocks T-cell activation by a mechanism of action distinct from cal...
Conversion to sirolimus for chronic renal allograft dysfunction: risk factors for graft loss and sev...
Contains fulltext : 50114.pdf (publisher's version ) (Closed access)Recent studies...
This study was designed to evaluate whether sirolimus (SRL) conversion effectively improves renal fu...
Sirolimus (SRL), a mammalian target of rapamycin inhibitor, is widely used in transplantation, but t...